{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:09:44Z","timestamp":1790514584987,"version":"4.1.0"},"reference-count":36,"publisher":"Royal College of General Practitioners","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJGP Open"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.3399\/bjgpopen20x101014","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T05:45:14Z","timestamp":1583300714000},"page":"bjgpopen20X101014","source":"Crossref","is-referenced-by-count":17,"title":["Combatting the misuse of benzodiazepines and related Z drugs in French general practice: a clinical review"],"prefix":"10.3399","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8849-7888","authenticated-orcid":false,"given":"Gaetan","family":"Gentile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"2020081209184384000_4.1.bjgpopen20X101014.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2016.08.001"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.2","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM) (2017) [Status report on the consumption of benzodiazepines in France \u2014 April 2017] \u00c9tat des lieux de la consommation des benzodiaz\u00e9pines en France \u2014 Avril 2017 (in French). 13 Feb 2020. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Etat-des-lieux-de-la-consommation-des-benzodiazepines-Point-d-Information."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.10.004"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.09.078"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.5","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12356"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.01.036"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.09.071"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.8","doi-asserted-by":"publisher","DOI":"10.2165\/11599460-000000000-00000"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.9","unstructured":"Berghaus G Sticht G Grellner W (2010) Meta-Analysis of empirical studies concerning the effects of medicines and illegal drugs including pharmacokinetics on safe driving (DRUID), (Cologne) 25 Feb 2020. https:\/\/www.bast.de\/Druid\/EN\/deliverales-list\/downloads\/Deliverable_1_1_2_B.pdf?__blob=publicationFile&v=1."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.006"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1996"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-018-2550-1"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.13","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12709"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.14","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011021"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.15","doi-asserted-by":"publisher","DOI":"10.3109\/10826084.2014.912226"},{"issue":"1","key":"2020081209184384000_4.1.bjgpopen20X101014.16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/YIC.0000000000000150","article-title":"Long-Term use of antipychotics in community-dwelling dementia patients: prevalence and profile accounting for unobservable time bias because of hospitalization","volume":"32","author":"Boucherie","year":"2017","journal-title":"Int Clinical Psychopharmacol"},{"issue":"41","key":"2020081209184384000_4.1.bjgpopen20X101014.17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3917\/pos.413.0205","article-title":"[Comparison of the consumption of benzidiazepines according to type of buprenorphine use in a cohort of new users] Comparaison de la consommation de benzodiaz\u00e9pines selon le type d'usage de la bupr\u00e9norphine dans une cohorte de nouveaux usagers (in French)","volume":"3","author":"Biboulet","year":"2010","journal-title":"Prat Organ Soins"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.18","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-016-0413-3"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.19","first-page":"1","article-title":"[Representations, motivations and drug use trajectory in adolescence] Repr\u00e9sentations, motivations et trajectoire d\u2019usage de drogue l\u2019adolescence (in French)","volume":"122","author":"Obradovic","year":"2017","journal-title":"Tendances"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.10.003"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.001"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.22","unstructured":"R\u00e9publique Fran\u00e7aise (1991) Arr\u00eat\u00e9 du 7 Octobre 1991 fixant la liste des substances de la liste I des substances v\u00e9n\u00e9neuses propri\u00e9t\u00e9s hypnotiques et\/ou anxiolytiques dont la dur\u00e9e de prescription est r\u00e9duite [Order of establishing the list of substances in List I of poisonous substances with hypnotic and \/ or anxiolytic properties whose prescription period is reduced]. 24 Feb 2020. https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=LEGITEXT000020690355."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.23","unstructured":"Juin HAS (2015) Arr\u00eat des benzodiaz\u00e9pines et m\u00e9dicaments apparent\u00e9s: d\u00e9marche du m\u00e9decin traitant en ambulatoire. 24 Feb 2020. https:\/\/www.has-sante.fr\/jcms\/c_2039712\/fr\/arret-des-benzodiazepines-et-medicaments-apparentes-fiche-memo."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.24","first-page":"104","article-title":"[Renewal of benzodiazepines beyond the recommended durations] Renouvellement des benzodiaz\u00e9pines au-del des dur\u00e9es recommand\u00e9es, Observation du processus d\u00e9cisionnel en m\u00e9decine g\u00e9n\u00e9rale (in French)","volume":"93","author":"Rat","year":"2010","journal-title":"Exercer"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2018.07.007"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.26","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12368"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.27","unstructured":"Rat C Penhouet G Gaultier A et al (2014) Did the new French pay-for-performance system modify benzodiazepine prescribing practices? BMC Health Serv Res 14(1). 301."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.28","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12401"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.29","unstructured":"ANSM (2013) [Rohypnol (flunitrazepam) 1mg \u2014 discontinuation of sale \u2014 update] Rohypnol (flunitraz\u00e9pam) 1mg \u2014 Arr\u00eat de commercialisation \u2014 Point d'information (in French). 13 Feb 2020. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Rohypnol-flunitrazepam-1-mg-Arret-de-commercialisation-Point-d-information."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2018.10.006"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.31","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12847"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.32","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.149252"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.33","unstructured":"Public Health England (2018) Prescribed medicines that may cause dependence or withdrawal: a review of the evidence on the scale and nature of problems with some prescription medicines and how they can be prevented and treated. 13 Feb 2020. www.gov.uk\/government\/news\/prescribed-medicines-that-may-cause-dependence-or-withdrawal."},{"key":"2020081209184384000_4.1.bjgpopen20X101014.34","doi-asserted-by":"publisher","DOI":"10.1186\/s12909-017-1100-3"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.35","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-019-0965-0"},{"key":"2020081209184384000_4.1.bjgpopen20X101014.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022046"}],"container-title":["BJGP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/bjgpopen20X101014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:01:41Z","timestamp":1666008101000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgpopen.org\/lookup\/doi\/10.3399\/bjgpopen20X101014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.3399\/bjgpopen20X101014"],"URL":"https:\/\/doi.org\/10.3399\/bjgpopen20x101014","relation":{},"ISSN":["2398-3795"],"issn-type":[{"value":"2398-3795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]}}}